Benzinga
22 Jul 2026, 18:25 UTC · 8w ago
Verdict
Headline leans bullish. We score ARWR +1.00 across four claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+1.00strongly bullish
What the story claims
4 claims · scored −1 bearish … +1 bullish
Arrowhead's plozasiran successfully met primary and secondary endpoints in two Phase 3 trials for hypertriglyceridemia, reducing triglyceride levels by 79-81%.
More positive than 98% of claims this week
Plozasiran demonstrated a 78% reduction in cumulative pancreatitis events across the broader patient group and a 100% reduction in high-risk patients compared to placebo.
Continue reading
5 related stories
More positive than 98% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 96% of claims this week
Arrowhead plans to submit a supplemental new drug application (sNDA) to the U.S. FDA before the end of 2026.
More positive than 84% of claims this week
The drug exhibited a favorable safety profile with no new safety concerns, hypersensitivity cases, or significant liver enzyme changes.
More positive than 76% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
Phase 3 trials for plozasiran showed strong efficacy in reducing blood fat and pancreatitis, leading to a 22% stock price increase.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Reuters
1d ago
−10.8%
Price is moving against the score
$66.48 vs $74.52 close before publication (Jul 21) · not market-adjusted
ARWR chart →
